CTOs on the Move

Navitor Pharmaceuticals

www.navitorpharma.com

 
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The companys proprietary drug discovery platform targets mTORC1, which responds to and integrates the cells response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitors therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The companys founding intellectual property is based on the groundbreaking discoveries ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Navitor Pharmaceuticals raised $11.3M on 03/19/2018

Similar Companies

West Virginia Biometrics Initiative

West Virginia Biometrics Initiative is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifeprint

Lifeprint is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inozyme

We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.

ACGT DNA Technologies

ACGT DNA Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asklepios BioPharmaceutical

Asklepios BioPharmaceutical, Inc. (AskBio) is a leading clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare diseases and other genetic disorders.